New drug aims to dissolve amyloid lumps in rare disease
NCT ID NCT07615270
First seen May 30, 2026 · Last updated Jun 12, 2026 · Updated 3 times
Summary
This early study tests a drug called CAEL-101/anselamimab in 5 adults with AL amyloidoma, a condition where abnormal protein builds up in tissues. The goal is to see if the drug binds to these deposits and helps shrink them. Participants will have imaging scans over 72 weeks to track changes in deposit size.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.